why choose us

First received: May 01, 2023

Clinical Trial: A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Pancreatic Ductal Adenocarcinoma

Study Type: INTERVENTIONAL


Official Title: Total Neoadjuvant NALIRIFOX Plus Ablative Dose Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Brief Summary: The researchers are doing this study to find out whether using the chemotherapy regimen NALIRIFOX in combination with ablative dose radiation therapy (AD-XRT) and the standard chemotherapy drug capecitabine is an effective treatment approach for people with locally advanced or borderline resectable pancreatic ductal adenocarcinoma (PDAC) before surgery.This type of treatment approach is called total neoadjuvant therapy (TNT).The researchers will also look at whether the sequence of the treatment approach…

Read more